Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure
Nitya Nathwani(City of Hope), Robert W. Chen, Chatchada Karanes(Erasmus MC Cancer Institute), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Stephen J. Forman(City Of Hope National Medical Center), Sandra H. Thomas(City Of Hope National Medical Center), Eileen Smith, Amrita Krishnan(City of Hope), Eric L. Sievers(Seagen (United States))
Cited by 28
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k